Terry Newcomb

821 total citations
19 papers, 635 citations indexed

About

Terry Newcomb is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Terry Newcomb has authored 19 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Genetics and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Terry Newcomb's work include Chronic Lymphocytic Leukemia Research (7 papers), Advanced Breast Cancer Therapies (3 papers) and DNA Repair Mechanisms (3 papers). Terry Newcomb is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Advanced Breast Cancer Therapies (3 papers) and DNA Repair Mechanisms (3 papers). Terry Newcomb collaborates with scholars based in United States, France and Italy. Terry Newcomb's co-authors include Lawrence A. Loeb, Margaret E. Black, Heather Wilson‐Robles, Qingshan Yang, Varsha Gandhi, Christophe Quéva, R. Dyche Mullins, Jesse E. Sisken, Fred C. Christians and L. K. Tkeshelashvili and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Terry Newcomb

19 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Terry Newcomb United States 12 391 155 110 103 85 19 635
Carlo Cosimo Campa Italy 14 748 1.9× 185 1.2× 71 0.6× 94 0.9× 59 0.7× 23 1.1k
Raouf Fetni Canada 15 481 1.2× 153 1.0× 34 0.3× 220 2.1× 85 1.0× 34 857
Chris Bartholomew United Kingdom 17 587 1.5× 239 1.5× 65 0.6× 134 1.3× 23 0.3× 36 904
Kyungsoo Ha United States 16 873 2.2× 130 0.8× 104 0.9× 240 2.3× 43 0.5× 31 1.1k
Laura Spinelli United Kingdom 11 524 1.3× 65 0.4× 57 0.5× 157 1.5× 44 0.5× 21 805
Mark R. Silvis United States 13 662 1.7× 58 0.4× 80 0.7× 134 1.3× 221 2.6× 19 1.1k
Enyuan Shang United States 17 921 2.4× 190 1.2× 118 1.1× 99 1.0× 44 0.5× 27 1.2k
Patricia A. Zipfel United States 16 596 1.5× 52 0.3× 79 0.7× 283 2.7× 39 0.5× 21 1.0k
Erik Kupperman United States 12 927 2.4× 60 0.4× 65 0.6× 319 3.1× 26 0.3× 17 1.2k
Satoshi Kofuji Japan 14 548 1.4× 53 0.3× 43 0.4× 80 0.8× 59 0.7× 30 822

Countries citing papers authored by Terry Newcomb

Since Specialization
Citations

This map shows the geographic impact of Terry Newcomb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terry Newcomb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terry Newcomb more than expected).

Fields of papers citing papers by Terry Newcomb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terry Newcomb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terry Newcomb. The network helps show where Terry Newcomb may publish in the future.

Co-authorship network of co-authors of Terry Newcomb

This figure shows the co-authorship network connecting the top 25 collaborators of Terry Newcomb. A scholar is included among the top collaborators of Terry Newcomb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terry Newcomb. Terry Newcomb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Brown, Jennifer R., Paolo Ghia, Jeffrey A. Jones, et al.. (2016). Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.. Journal of Clinical Oncology. 34(15_suppl). 7531–7531. 2 indexed citations
2.
Wierda, William G., Steven Coutré, Ian W. Flinn, et al.. (2016). Management of transaminase elevations in patients receiving idelalisib.. Journal of Clinical Oncology. 34(15_suppl). 7532–7532. 2 indexed citations
3.
O’Brien, Susan, Andrew Davies, Ian W. Flinn, et al.. (2015). Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. Blood. 126(23). 1747–1747. 1 indexed citations
4.
5.
Coutré, Steven, Jacqueline C. Barrientos, Jennifer R. Brown, et al.. (2015). Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.. Journal of Clinical Oncology. 33(15_suppl). e18030–e18030. 14 indexed citations
6.
Yang, Qingshan, et al.. (2015). Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clinical Cancer Research. 21(7). 1537–1542. 172 indexed citations
7.
O’Riordan, Thomas G., Peter Hodsman, John H. Ansede, et al.. (2013). Acute Hyperkalemia Associated with Inhalation of a Potent ENaC Antagonist: Phase 1 Trial of GS-9411. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 27(3). 200–208. 45 indexed citations
8.
Jin, Feng, Huafeng Zhou, Xiaoming Li, et al.. (2013). Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies. Blood. 122(21). 5054–5054. 4 indexed citations
9.
Harvey, J. C., James Cantrell, Alan Cartmell, et al.. (2001). Mitoxantrone and Paclitaxel Combination Chemotherapy in Metastatic Breast Cancer. Cancer Investigation. 19(3). 225–233. 3 indexed citations
10.
Weisman-Shomer, Pnina, et al.. (2000). Human Ku Antigen Tightly Binds and Stabilizes a Tetrahelical Form of the Fragile X Syndrome d(CGG) Expanded Sequence. Journal of Biological Chemistry. 275(42). 33134–33141. 24 indexed citations
11.
Schriner, Samuel E., Charles E. Ogburn, Annette C. Smith, et al.. (2000). Levels of dna damage are unaltered in mice overexpressing human catalase in nuclei. Free Radical Biology and Medicine. 29(7). 664–673. 29 indexed citations
12.
Quaife, Carol J., et al.. (1999). Metallothionein Overexpression Supresses Hepatic Hyperplasia Induced by Hepatitis B Surface Antigen. Toxicology and Applied Pharmacology. 155(2). 107–116. 14 indexed citations
13.
Newcomb, Terry, et al.. (1999). Detection of tandem CC → TT mutations induced by oxygen radicals using mutation-specific PCR. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 427(1). 21–30. 19 indexed citations
14.
Jackson, Aimee L., Terry Newcomb, & Lawrence A. Loeb. (1998). Origin of Multiple Mutations in Human Cancers. Drug Metabolism Reviews. 30(2). 285–304. 10 indexed citations
15.
Black, Margaret E., Terry Newcomb, Heather Wilson‐Robles, & Lawrence A. Loeb. (1996). Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.. Proceedings of the National Academy of Sciences. 93(8). 3525–3529. 221 indexed citations
16.
Christians, Fred C., et al.. (1995). Potential Sources of Multiple Mutations in Human Cancers. Preventive Medicine. 24(4). 329–332. 18 indexed citations
17.
Baybutt, Richard, John E. Smith, Mark N. Gillespie, Terry Newcomb, & Yu‐Yan Yeh. (1994). Arachidonic acid and eicosapentaenoic acid stimulate type II pneumocyte surfactant secretion. Lipids. 29(8). 535–539. 11 indexed citations
18.
Mullins, R. Dyche, Terry Newcomb, Gabriela Pavlínková, et al.. (1993). Serum- and bradykinin-induced calcium transients in familial Alzheimer's fibroblasts. Neurobiology of Aging. 14(5). 447–455. 32 indexed citations
19.
Newcomb, Terry, R. Dyche Mullins, & Jesse E. Sisken. (1993). Altered calcium regulation in SV40-transformed Swiss 3T3 fibroblasts. Cell Calcium. 14(7). 539–549. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlo Cosimo Campa Breakdown of academic impact, for papers by Raouf Fetni Breakdown of academic impact, for papers by Chris Bartholomew Breakdown of academic impact, for papers by Kyungsoo Ha Breakdown of academic impact, for papers by Laura Spinelli Breakdown of academic impact, for papers by Mark R. Silvis Breakdown of academic impact, for papers by Enyuan Shang Breakdown of academic impact, for papers by Patricia A. Zipfel Breakdown of academic impact, for papers by Erik Kupperman Breakdown of academic impact, for papers by Satoshi Kofuji
Rankless by CCL
2026